nitroglycerin (IMX-150) / PreMD - LARVOL DELTA

PET/CT based imaging biomarkers for response prediction of stage IV NSCLC treated with paclitaxel–carboplatin–bevacizumab with or without nitroglycerin (ELCC 2016) - P2, N=60; NCT01171170; “There were more PET-based responders in week 3 than CT-based responders…PET showed a high sensitivity whereas CT showed a high specificity…PET parameters (max and peak SUV) reached a significant AUC to predict RECIST analysis.”

Biomarker • Biosimilar • Non Small Cell Lung Cancer • Oncology

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG) (clinicaltrials.gov) - P3; N=629; Completed; Sponsor: The Medicines Company; Trial completion date: Mar 2006 ->Apr 2005

Trial completion date • Biosimilar • Dyslipidemia